{"ticker": {"uuid": "9f71bec9-784b-4141-9497-eb37d0e5f3ee", "symbol": "CHM", "name": "Chimeric Therapeutics Limited", "exchange": "ASX", "country": "AU", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Chimeric Therapeutics Issues 325 Warrants as Part of Second Tranche Convertible Notes Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxOTU8tS0puWDdSaTNKS3gtckE2cVVYNEdrcFNyNmRYY3BFeFBmMHpnT1JPVnpad1hBM092SXc0MlIycmpjdnlyRmlKRWtLQ2VDaDlDbDlTU2oxeThHU2pneTBYSXc0NHpzZ2NCTExXVzlmVWlWR3BGNmpiRkJPb3FQYTFPdDNMUVg3V2tYLWd1VnhNemlvT3U1aWlYdkN3TktObG13UlNJNDRwZFVpaGcyOEVPZlRuVlNDTmYxVkRFNzlFVXllRnpGNFF3amprUC1NLUZj?oc=5", "source_name": "Kalkine", "published_at": "2026-07-17T08:04:13+00:00", "published_display": "17 Jul 2026 08:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimeric Therapeutics Issues 650 Convertible Notes Worth AUD 650,000 in Second Tranche Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxOQkV2SHZfY05NVzc1SFBBOEFVSm1tUkp4a1h5SmpqVVFremtvd2FVUU1VNGNBcEkzTGYzcmF5UUpmeGNBZHBBemE2R29mLUtjN0VzSFQxU2h5c05WQzZVRDdiT0dfcVQtejEwdFZoV3NkMzRIaHdWSlgyUW9DdXQ0a1RQaGp1eDk4MUo0dmp2TjdyeUs3STNIdDZyTkRVeENnbXlBeXZWVGxicjBPUkRnMjBuV1BTdmhSN05jeFM0bEhQNVFzNGtaelVqOXNxOTR2VUNV?oc=5", "source_name": "Kalkine", "published_at": "2026-07-17T08:04:13+00:00", "published_display": "17 Jul 2026 08:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimeric Therapeutics (ASX:CHM) posts 40% tumour shrinkage at top dose in CAR-T trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxQMUFlYWpod192LWp5QzR6OGJxS2xRT0lQQWxpbVFSRkl2STg2UjB3eElTbWhfeXB2bGZHY2VHZjZrb1hiMXBVVmt6UmRIUmdBMDN4UW5rZW1ORDAtWW1YMzlkSWZtM1VYamVoR0kzTzFsMGtXdTVxZzU2VGxPNU5LUzNESmVMT3gz?oc=5", "source_name": "Stocks Down Under", "published_at": "2026-07-16T00:29:59+00:00", "published_display": "16 Jul 2026 00:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimeric Therapeutics Reports Tumour Shrinkage of 17\u201340% in New Dose Level 3 CAR-T Cell Therapy Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOT2ZBeF9oUFY1RHlpODU3SmNDcVVpMGoyLTNfZ0xNdG51aXFTUGVnNkRzZk05eklxOVRmUFBzQV9RQkFsRnNCY2xHVjZUb1lJZ3EyT2VCU2VvaFNWNmtEcVQ1WTRfSmZZUUlfTXYzMlBzUVlVWEFkd21DT2xUbjF4QU00ejFvSHE2aEtqX2dKSUZEQV9qenFpN3NtWXBvVWZLVUR3aVdIOTRxaFF3dl9ObXRRclpnV3FfM2xRWVAta0kwVHlvTnFwdXpMSFlxUmR1c21jS2NFRQ?oc=5", "source_name": "Kalkine", "published_at": "2026-07-15T23:53:43+00:00", "published_display": "15 Jul 2026 23:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimeric Therapeutics Reports Expiry of 45,000 Unexercised Options", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxNZjlScDRfUUpPQUVpSWo5b3JlTFBRR1poUmYzNE45ZzdINkppTnh2SkRYaW9xYnlIUGxvUk1fYVdVUkkwOW5tYXpveGlWekh5N2RmVkVoY05abEk5M0lZNFQzWnBVRUFFSHZURzlLYmpzSDIzMVk1b09DMjV3TEg5U3N5dkZxbE5hZEtsSXJQMFBKQ0xmUkJmU2xXbjAxZnZrZF9jcmNsSlVSci1IODJ0SmZXaVU0aVR0ZEN2eXZjUjhPakxNcV8xQ0Z1ZDFoUjFXRE9naVNLUzZfVC1zdFlCUQ?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-15T06:58:57+00:00", "published_display": "15 Jul 2026 06:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimeric Therapeutics Converts Convertible Notes into 1.41 Million Ordinary Shares at $0.039 Per Security", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxPQmVqckFXeW5sRlhuWDhfRndnZHhLYVB6dDBVWVYtYWRycVFicUZFOWJsd09ydHp0LWxSMlY4ZjV6b0JNSEFzWHppMjZ1Zkw5UjhQYVVTVmItbXRZLWY1bzJvVEdpR1B0TEx0VjN1THVvZjhfbnh0cm4wT1hCU19zLXpUZmJiQm9uckVCZThoM0EwbFZZOVNXendxNFY2VWlKMnloVUdMQXFIN3B4QlNNZmJ0ZTlLU3dFaFBWbHJzanBfWXZ1QmhiTkU1VWxSUEJQTWxyY0FkSkNlUEVT?oc=5", "source_name": "Kalkine", "published_at": "2026-07-14T09:54:12+00:00", "published_display": "14 Jul 2026 09:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Chimeric Therapeutics (ASX: CHM) Positioning for a Biotechnology Recovery?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPSVh4TzdERjVIT2ZXNzZvMDd3TmFSYkZPd1pRNjJUUGg2RDRxU2dYM1Q4dF9qNTgzTURKWkJfM0ZHbXo1akFteG5nV3M0czl1YTBTQy1jcWhsZmFoNjh4akQ3NS1kR3RWRlBOMTFzdk94Q3JXOXFHRXNPVVd3TXpOY3JsVVNaZ19YeUVXOWpabHlqQXhVMnZGTTNMUzJFbllNVGM5SWZoOTlfM0p1akpoWm1B?oc=5", "source_name": "Kalkine", "published_at": "2026-07-13T13:46:00+00:00", "published_display": "13 Jul 2026 13:46", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimeric Therapeutics (ASX:CHM) Jumps as Cell-Therapy Investors Return to the ASX Micro-Cap", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOam80cXhSeFNDdnFxVXZsVUk1cVkwQ3dzQkJ2SHlVRXBHdm1Na201NHhiY2g4amgzN0tna2NyN1NKNmYwYXVhN3dtQm42STNqbE5TZFRab1lyWW9nWUE5bHZkcmtHeGR1T3FvR0VGVHFFU2pkV1MxbG9yQ1VnMEVINjMwTnJZTWtOTThHcjRrSGJIX3FWTGJ3QzZPZjEwZW5LSE54UHdPbXpGdHFpOTBOQ1dHZHNmSzEwbi1CejJXVTBvdWtCUlE?oc=5", "source_name": "Kalkine", "published_at": "2026-07-13T08:17:00+00:00", "published_display": "13 Jul 2026 08:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimeric Therapeutics Limited (ASX:CHM): Is This CAR-T Biotech Story Still Building Momentum?", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxPWXFJTEk0RFAwODdqSFExNTNyU3JZSzVyTFhoYUtPZjNQczdQUTNVaWQyVV9mcTg4NU1STjMwVGFpX2ZOV0YzTnR4MmliMk1RNEEydkxBUm41UFRad09GdzJZa21RVGNTUFJ0V0lVZGN5TjNOdEl5UUFld1dEanJ5a1J3MnNpY2YtaHpjR3ZQd3dsZlBBaDJhYjVPWFRRVGEzaGtGbXVZeVVBTkRGR1llOUxzSjhDUW43aDZrNzl1d3RLN0pIa0ZmSmdWbUlyUQ?oc=5", "source_name": "Kalkine", "published_at": "2026-07-10T11:48:00+00:00", "published_display": "10 Jul 2026 11:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What's Driving Chimeric Therapeutics' (ASX: CHM) Share Price?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQY3hULTV2Nk1XNlhCUUdXSnFjRS05WEFISWFTVlI4YlR1QXFkcmhueWtJZjE5MjF1ckZrY2N0cHVBdDhOT01Nd1ByUF9yWUhjaHhnNlBjUkJuVWowbGFRd0RQWUp0TFIzTWNDbEdzbUpTbFlIMG5iY1p3ZVIybTlzaGtPa3JXM0xiOXBvU3Q5VksybmVYczFGcWJR?oc=5", "source_name": "Kalkine", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimeric Therapeutics Board Member Eric Sullivan Retires", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxNbW0teUp0bzAyMkN4Nm5fN2ZEaDdxaHlmZTgzY2FaUjloR3lVVDV4cEVwQThjbmRNUnpoTXJMYURDbDUtdFptd1VZUnRtZlpjRFpHVkVHRmd4U24ydFFYc3c1Wk9HdmYtYnFxTHRIZDh6dGNGdWQtMDBwRzdoSG5jdTU3RmtrQzlvckg0RFNQQTlJSkhDbXFobEdBektwVXh5Z2tGdHdMZzc5aVZsbWFkUFNTaEsxUkhmWXhuaXdiNTcwX0ItVXI4QzJmXzFWUzEyYzBB?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-06T23:30:00+00:00", "published_display": "06 Jul 2026 23:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimeric Therapeutics Converts Convertible Notes Into 1.77 Million New Ordinary Shares at $0.048 Each", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQdUtMMm1LTW5hYWExcjYzd015UjNwNkE5SDQ2N1Y3NF8tUU5EX0g4cWdpVDI0d1JBNzlFNDFPZFFEcHdSRGIzVF92d214Xzd3aWQyNUVFakFiN29Ec2c1OTFYSkVicGtIY3BINkdDU3kxWnpTcHZodml5QTdGWUlYOVY2bEZpbkdVM0kyLUVWU0pGcG1rUFVrOC0zRnh1WnlpNjBzckx6VTczT2F3bkFtRnVqSzFhcUZ0c2ZRaEx2LXE1RWVYaTVucTRJZ2l6MjdUOHhBZnhSMA?oc=5", "source_name": "Kalkine", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimeric Therapeutics (ASX:CHM): Could This Cell Therapy Stock Become a Biotech Comeback Story?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxORm94V0l5ay14a2p5WllrQnpTaGFtZEthVFZWSUozMmN2TXk2LWxhN1NNbHVpbVVVUTFxYVVUOFlMYWVYaU9UUzZGYjhsN1ZPekFmc19rc3RJeWc4OGY0QVcwZ09WdkI2MFg3WW8wa3pCZ01CRTlnUWpNeU1ScFY1UzFtbVNxNHRlMDRMOXpqRnpleGtBQmJBVE1YZXlkQnk4Y0xDOENkS204SnQ5Ql9laHE2LWszb0h1ZmJWX2kxaERra2l2OWpyTg?oc=5", "source_name": "Kalkine", "published_at": "2026-07-01T10:18:00+00:00", "published_display": "01 Jul 2026 10:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimeric Therapeutics (ASX:CHM) Shares Jump 15% Today- Here\u2019s Why?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNVDM1Nzg2eVJQaEJJdUVGYWgyYld4clNHU2UxTnpQak15bloxY0p1Q3Q2NnVKZzF1VHFLaXNuWUVTaDJKM1FJV2VMc0pzckMtRlhBRS1EUjZiYV85by0ydE93SWgwa0RMclpnUExaaGpZNU1OLTlmSTJSWFRpQ0kzdHFIVU8yYUxxUXBDbklPdW82SUJ1RGtRSFV3azY1VUk?oc=5", "source_name": "Kalkine", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insiders Who Purchased AU$3.01m Of Chimeric Therapeutics Stock May Not Have Expected 18% Tumble", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPZi1MRWk3RkZUMVBTRVJpNlplV1NOc2RMWDdFMk1USzdkR1RBM3RWTHdkS3dlYTUzZkxCYnZERFM2UzVQSkFnLUhwVXlDbmtCZ3UxOUZVRjVhd1lWRDFJelVfLWp3elppWkM2WlJjVXdwTS1aVXg3V2hoNlpaRzdBc1FjQkc2a2lVdGdiNnZRRU8tTE5CZ2ZJ?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Top 10 at 11: Chimeric has complete response in 60pc of leukemia cohort; market slides on open", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNQ3hxVkNRRU5fNU4tYWdqdUZQbDU0dGJsUDNJbExIS2h1SHJTNHVPanFRRExwR3RDbWFLMnpsaGtuZGdFUEdUajljN1VlYXZMc0hUVF9mTjVtZHhManhlNjVJR3lxZ2VoWURwV1B2NTJmMjRzaXY1aVAxRWxZOGtlTS1DdVk0eENwQU8xa1VXSTc3WkhuaHpXR3A1QTFoTDRLR3FDbG9SeEoyTnVmUTRrczNQanZIOGN6SjV2MGlR?oc=5", "source_name": "Stockhead", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimeric Therapeutics Secures $8.4 Million Funding to Advance CHM CDH17 Program", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOV1ptVGFqWTZDSzh3bmt0b2M2MWJ3U0VYc2t6aHRuZXlBWDdqbEFGc0ZoaEJnTTlQRU5sLS1YU25mTm9XS3pVeEZMUlE4VGdZUmROSEJHOVQ5ZndSTEp5ZWlOVEhFTmRPMjlMTVZGZTVIUHdNbW1jMm1rM1BPNnFSNW02WVUzZDlNaVc0THpCYnNiRFVwdUQtQTZZVW9HSWFOcG0wUHNtX3F6TUJyd0dncDAyZWdJa1dNaXZJ?oc=5", "source_name": "Sharecafe", "published_at": "2025-12-23T08:00:00+00:00", "published_display": "23 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimeric Therapeutics (ASX:CHM) is headed for the CAR-T \u2018Big Time\u2019", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE5mdU5oZGJGVTBfd1MtVDVpOHZWTVU3a3VKWXpHMDdzanpfRHo3TnQzUndMc0FRa1AweVR2X0ZKa0JGQUpOQkZZaVh1M3VvaHRnSDVHb0htNGdycEhQX3ljREJncGQ1UDZ5Z091S09qaWUxTEk2cFpz?oc=5", "source_name": "Stocks Down Under", "published_at": "2025-12-11T23:49:37+00:00", "published_display": "11 Dec 2025 23:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimeric Therapeutics provides update on CHM CDH17 CAR-T clinical trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOcWVsVDJSaVRZWGd0Y3pmaVZHbXQ2NGxOeVh0M3FPVnFod0tlZUFZTmVYRWY3N2F6YzFfUTlMOHFOcXhfcVdnQWVUblZUN3M0NGtsOTdqT2Vob0NuZHdqTkZaNUx6ODFWZUM1M0pBNVFTV3BWUEljRGppQmNsMUh6ZU13ZHFwS1pzYmFpTWgzbTJ1aXdwNmZlQ0FQeVlnOXBETGU4b0gxOWc2MFE?oc=5", "source_name": "BiotechDispatch", "published_at": "2025-08-05T07:00:00+00:00", "published_display": "05 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimeric Therapeutics (ASX:CHM): Solid prospects for licensing deals", "summary": "", "url": "https://news.google.com/rss/articles/CBMidEFVX3lxTFBjLUtieWFoWDFtWWpKLWNVLXdOU0tvdWVsZ0ljci1aeXc5TVBuZy1aaTRhbTN6Y0JJMm1SanFjMTJnQV9xbDZOWnhGWU9lbHN4ekNuRE1KT0MtQUZqR1h6TjktSnBZX2NhekJ6cjZ0em1IUDVD?oc=5", "source_name": "Stocks Down Under", "published_at": "2024-06-05T06:46:13+00:00", "published_display": "05 Jun 2024 06:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CHM Stock Price and Chart \u2014 ASX:CHM", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE9URlc5NWtvT2tCVndCZ3pYZW9tS0Z3VHU3NG1TeE5RRE9seFJfX0ctLU5TS3Y1QmxWMGFIUnVmLTFiLS1GSDFmR3IzTTRHeUlYdmhUOG84WQ?oc=5", "source_name": "TradingView", "published_at": "2021-01-18T12:01:57+00:00", "published_display": "18 Jan 2021 12:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Chimeric Therapeutics Issues 325 Warrants as Part of Second Tranche Convertible Notes Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxOTU8tS0puWDdSaTNKS3gtckE2cVVYNEdrcFNyNmRYY3BFeFBmMHpnT1JPVnpad1hBM092SXc0MlIycmpjdnlyRmlKRWtLQ2VDaDlDbDlTU2oxeThHU2pneTBYSXc0NHpzZ2NCTExXVzlmVWlWR3BGNmpiRkJPb3FQYTFPdDNMUVg3V2tYLWd1VnhNemlvT3U1aWlYdkN3TktObG13UlNJNDRwZFVpaGcyOEVPZlRuVlNDTmYxVkRFNzlFVXllRnpGNFF3amprUC1NLUZj?oc=5", "source_name": "Kalkine", "published_at": "2026-07-17T08:04:13+00:00", "published_display": "17 Jul 2026 08:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimeric Therapeutics Issues 650 Convertible Notes Worth AUD 650,000 in Second Tranche Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxOQkV2SHZfY05NVzc1SFBBOEFVSm1tUkp4a1h5SmpqVVFremtvd2FVUU1VNGNBcEkzTGYzcmF5UUpmeGNBZHBBemE2R29mLUtjN0VzSFQxU2h5c05WQzZVRDdiT0dfcVQtejEwdFZoV3NkMzRIaHdWSlgyUW9DdXQ0a1RQaGp1eDk4MUo0dmp2TjdyeUs3STNIdDZyTkRVeENnbXlBeXZWVGxicjBPUkRnMjBuV1BTdmhSN05jeFM0bEhQNVFzNGtaelVqOXNxOTR2VUNV?oc=5", "source_name": "Kalkine", "published_at": "2026-07-17T08:04:13+00:00", "published_display": "17 Jul 2026 08:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimeric Therapeutics (ASX:CHM) posts 40% tumour shrinkage at top dose in CAR-T trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxQMUFlYWpod192LWp5QzR6OGJxS2xRT0lQQWxpbVFSRkl2STg2UjB3eElTbWhfeXB2bGZHY2VHZjZrb1hiMXBVVmt6UmRIUmdBMDN4UW5rZW1ORDAtWW1YMzlkSWZtM1VYamVoR0kzTzFsMGtXdTVxZzU2VGxPNU5LUzNESmVMT3gz?oc=5", "source_name": "Stocks Down Under", "published_at": "2026-07-16T00:29:59+00:00", "published_display": "16 Jul 2026 00:29", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimeric Therapeutics Reports Tumour Shrinkage of 17\u201340% in New Dose Level 3 CAR-T Cell Therapy Data", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxOT2ZBeF9oUFY1RHlpODU3SmNDcVVpMGoyLTNfZ0xNdG51aXFTUGVnNkRzZk05eklxOVRmUFBzQV9RQkFsRnNCY2xHVjZUb1lJZ3EyT2VCU2VvaFNWNmtEcVQ1WTRfSmZZUUlfTXYzMlBzUVlVWEFkd21DT2xUbjF4QU00ejFvSHE2aEtqX2dKSUZEQV9qenFpN3NtWXBvVWZLVUR3aVdIOTRxaFF3dl9ObXRRclpnV3FfM2xRWVAta0kwVHlvTnFwdXpMSFlxUmR1c21jS2NFRQ?oc=5", "source_name": "Kalkine", "published_at": "2026-07-15T23:53:43+00:00", "published_display": "15 Jul 2026 23:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimeric Therapeutics Reports Expiry of 45,000 Unexercised Options", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxNZjlScDRfUUpPQUVpSWo5b3JlTFBRR1poUmYzNE45ZzdINkppTnh2SkRYaW9xYnlIUGxvUk1fYVdVUkkwOW5tYXpveGlWekh5N2RmVkVoY05abEk5M0lZNFQzWnBVRUFFSHZURzlLYmpzSDIzMVk1b09DMjV3TEg5U3N5dkZxbE5hZEtsSXJQMFBKQ0xmUkJmU2xXbjAxZnZrZF9jcmNsSlVSci1IODJ0SmZXaVU0aVR0ZEN2eXZjUjhPakxNcV8xQ0Z1ZDFoUjFXRE9naVNLUzZfVC1zdFlCUQ?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-15T06:58:57+00:00", "published_display": "15 Jul 2026 06:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimeric Therapeutics Converts Convertible Notes into 1.41 Million Ordinary Shares at $0.039 Per Security", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3AFBVV95cUxPQmVqckFXeW5sRlhuWDhfRndnZHhLYVB6dDBVWVYtYWRycVFicUZFOWJsd09ydHp0LWxSMlY4ZjV6b0JNSEFzWHppMjZ1Zkw5UjhQYVVTVmItbXRZLWY1bzJvVEdpR1B0TEx0VjN1THVvZjhfbnh0cm4wT1hCU19zLXpUZmJiQm9uckVCZThoM0EwbFZZOVNXendxNFY2VWlKMnloVUdMQXFIN3B4QlNNZmJ0ZTlLU3dFaFBWbHJzanBfWXZ1QmhiTkU1VWxSUEJQTWxyY0FkSkNlUEVT?oc=5", "source_name": "Kalkine", "published_at": "2026-07-14T09:54:12+00:00", "published_display": "14 Jul 2026 09:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Chimeric Therapeutics (ASX: CHM) Positioning for a Biotechnology Recovery?", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPSVh4TzdERjVIT2ZXNzZvMDd3TmFSYkZPd1pRNjJUUGg2RDRxU2dYM1Q4dF9qNTgzTURKWkJfM0ZHbXo1akFteG5nV3M0czl1YTBTQy1jcWhsZmFoNjh4akQ3NS1kR3RWRlBOMTFzdk94Q3JXOXFHRXNPVVd3TXpOY3JsVVNaZ19YeUVXOWpabHlqQXhVMnZGTTNMUzJFbllNVGM5SWZoOTlfM0p1akpoWm1B?oc=5", "source_name": "Kalkine", "published_at": "2026-07-13T13:46:00+00:00", "published_display": "13 Jul 2026 13:46", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimeric Therapeutics (ASX:CHM) Jumps as Cell-Therapy Investors Return to the ASX Micro-Cap", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxOam80cXhSeFNDdnFxVXZsVUk1cVkwQ3dzQkJ2SHlVRXBHdm1Na201NHhiY2g4amgzN0tna2NyN1NKNmYwYXVhN3dtQm42STNqbE5TZFRab1lyWW9nWUE5bHZkcmtHeGR1T3FvR0VGVHFFU2pkV1MxbG9yQ1VnMEVINjMwTnJZTWtOTThHcjRrSGJIX3FWTGJ3QzZPZjEwZW5LSE54UHdPbXpGdHFpOTBOQ1dHZHNmSzEwbi1CejJXVTBvdWtCUlE?oc=5", "source_name": "Kalkine", "published_at": "2026-07-13T08:17:00+00:00", "published_display": "13 Jul 2026 08:17", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimeric Therapeutics Limited (ASX:CHM): Is This CAR-T Biotech Story Still Building Momentum?", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxPWXFJTEk0RFAwODdqSFExNTNyU3JZSzVyTFhoYUtPZjNQczdQUTNVaWQyVV9mcTg4NU1STjMwVGFpX2ZOV0YzTnR4MmliMk1RNEEydkxBUm41UFRad09GdzJZa21RVGNTUFJ0V0lVZGN5TjNOdEl5UUFld1dEanJ5a1J3MnNpY2YtaHpjR3ZQd3dsZlBBaDJhYjVPWFRRVGEzaGtGbXVZeVVBTkRGR1llOUxzSjhDUW43aDZrNzl1d3RLN0pIa0ZmSmdWbUlyUQ?oc=5", "source_name": "Kalkine", "published_at": "2026-07-10T11:48:00+00:00", "published_display": "10 Jul 2026 11:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What's Driving Chimeric Therapeutics' (ASX: CHM) Share Price?", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxQY3hULTV2Nk1XNlhCUUdXSnFjRS05WEFISWFTVlI4YlR1QXFkcmhueWtJZjE5MjF1ckZrY2N0cHVBdDhOT01Nd1ByUF9yWUhjaHhnNlBjUkJuVWowbGFRd0RQWUp0TFIzTWNDbEdzbUpTbFlIMG5iY1p3ZVIybTlzaGtPa3JXM0xiOXBvU3Q5VksybmVYczFGcWJR?oc=5", "source_name": "Kalkine", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimeric Therapeutics Board Member Eric Sullivan Retires", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxNbW0teUp0bzAyMkN4Nm5fN2ZEaDdxaHlmZTgzY2FaUjloR3lVVDV4cEVwQThjbmRNUnpoTXJMYURDbDUtdFptd1VZUnRtZlpjRFpHVkVHRmd4U24ydFFYc3c1Wk9HdmYtYnFxTHRIZDh6dGNGdWQtMDBwRzdoSG5jdTU3RmtrQzlvckg0RFNQQTlJSkhDbXFobEdBektwVXh5Z2tGdHdMZzc5aVZsbWFkUFNTaEsxUkhmWXhuaXdiNTcwX0ItVXI4QzJmXzFWUzEyYzBB?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-07-06T23:30:00+00:00", "published_display": "06 Jul 2026 23:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimeric Therapeutics Converts Convertible Notes Into 1.77 Million New Ordinary Shares at $0.048 Each", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxQdUtMMm1LTW5hYWExcjYzd015UjNwNkE5SDQ2N1Y3NF8tUU5EX0g4cWdpVDI0d1JBNzlFNDFPZFFEcHdSRGIzVF92d214Xzd3aWQyNUVFakFiN29Ec2c1OTFYSkVicGtIY3BINkdDU3kxWnpTcHZodml5QTdGWUlYOVY2bEZpbkdVM0kyLUVWU0pGcG1rUFVrOC0zRnh1WnlpNjBzckx6VTczT2F3bkFtRnVqSzFhcUZ0c2ZRaEx2LXE1RWVYaTVucTRJZ2l6MjdUOHhBZnhSMA?oc=5", "source_name": "Kalkine", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimeric Therapeutics (ASX:CHM): Could This Cell Therapy Stock Become a Biotech Comeback Story?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxORm94V0l5ay14a2p5WllrQnpTaGFtZEthVFZWSUozMmN2TXk2LWxhN1NNbHVpbVVVUTFxYVVUOFlMYWVYaU9UUzZGYjhsN1ZPekFmc19rc3RJeWc4OGY0QVcwZ09WdkI2MFg3WW8wa3pCZ01CRTlnUWpNeU1ScFY1UzFtbVNxNHRlMDRMOXpqRnpleGtBQmJBVE1YZXlkQnk4Y0xDOENkS204SnQ5Ql9laHE2LWszb0h1ZmJWX2kxaERra2l2OWpyTg?oc=5", "source_name": "Kalkine", "published_at": "2026-07-01T10:18:00+00:00", "published_display": "01 Jul 2026 10:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimeric Therapeutics (ASX:CHM) Shares Jump 15% Today- Here\u2019s Why?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNVDM1Nzg2eVJQaEJJdUVGYWgyYld4clNHU2UxTnpQak15bloxY0p1Q3Q2NnVKZzF1VHFLaXNuWUVTaDJKM1FJV2VMc0pzckMtRlhBRS1EUjZiYV85by0ydE93SWgwa0RMclpnUExaaGpZNU1OLTlmSTJSWFRpQ0kzdHFIVU8yYUxxUXBDbklPdW82SUJ1RGtRSFV3azY1VUk?oc=5", "source_name": "Kalkine", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insiders Who Purchased AU$3.01m Of Chimeric Therapeutics Stock May Not Have Expected 18% Tumble", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxPZi1MRWk3RkZUMVBTRVJpNlplV1NOc2RMWDdFMk1USzdkR1RBM3RWTHdkS3dlYTUzZkxCYnZERFM2UzVQSkFnLUhwVXlDbmtCZ3UxOUZVRjVhd1lWRDFJelVfLWp3elppWkM2WlJjVXdwTS1aVXg3V2hoNlpaRzdBc1FjQkc2a2lVdGdiNnZRRU8tTE5CZ2ZJ?oc=5", "source_name": "Market source", "published_at": "2026-05-08T07:00:00+00:00", "published_display": "08 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Top 10 at 11: Chimeric has complete response in 60pc of leukemia cohort; market slides on open", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNQ3hxVkNRRU5fNU4tYWdqdUZQbDU0dGJsUDNJbExIS2h1SHJTNHVPanFRRExwR3RDbWFLMnpsaGtuZGdFUEdUajljN1VlYXZMc0hUVF9mTjVtZHhManhlNjVJR3lxZ2VoWURwV1B2NTJmMjRzaXY1aVAxRWxZOGtlTS1DdVk0eENwQU8xa1VXSTc3WkhuaHpXR3A1QTFoTDRLR3FDbG9SeEoyTnVmUTRrczNQanZIOGN6SjV2MGlR?oc=5", "source_name": "Stockhead", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimeric Therapeutics Secures $8.4 Million Funding to Advance CHM CDH17 Program", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOV1ptVGFqWTZDSzh3bmt0b2M2MWJ3U0VYc2t6aHRuZXlBWDdqbEFGc0ZoaEJnTTlQRU5sLS1YU25mTm9XS3pVeEZMUlE4VGdZUmROSEJHOVQ5ZndSTEp5ZWlOVEhFTmRPMjlMTVZGZTVIUHdNbW1jMm1rM1BPNnFSNW02WVUzZDlNaVc0THpCYnNiRFVwdUQtQTZZVW9HSWFOcG0wUHNtX3F6TUJyd0dncDAyZWdJa1dNaXZJ?oc=5", "source_name": "Sharecafe", "published_at": "2025-12-23T08:00:00+00:00", "published_display": "23 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimeric Therapeutics (ASX:CHM) is headed for the CAR-T \u2018Big Time\u2019", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE5mdU5oZGJGVTBfd1MtVDVpOHZWTVU3a3VKWXpHMDdzanpfRHo3TnQzUndMc0FRa1AweVR2X0ZKa0JGQUpOQkZZaVh1M3VvaHRnSDVHb0htNGdycEhQX3ljREJncGQ1UDZ5Z091S09qaWUxTEk2cFpz?oc=5", "source_name": "Stocks Down Under", "published_at": "2025-12-11T23:49:37+00:00", "published_display": "11 Dec 2025 23:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimeric Therapeutics provides update on CHM CDH17 CAR-T clinical trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOcWVsVDJSaVRZWGd0Y3pmaVZHbXQ2NGxOeVh0M3FPVnFod0tlZUFZTmVYRWY3N2F6YzFfUTlMOHFOcXhfcVdnQWVUblZUN3M0NGtsOTdqT2Vob0NuZHdqTkZaNUx6ODFWZUM1M0pBNVFTV3BWUEljRGppQmNsMUh6ZU13ZHFwS1pzYmFpTWgzbTJ1aXdwNmZlQ0FQeVlnOXBETGU4b0gxOWc2MFE?oc=5", "source_name": "BiotechDispatch", "published_at": "2025-08-05T07:00:00+00:00", "published_display": "05 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Chimeric Therapeutics (ASX:CHM): Solid prospects for licensing deals", "summary": "", "url": "https://news.google.com/rss/articles/CBMidEFVX3lxTFBjLUtieWFoWDFtWWpKLWNVLXdOU0tvdWVsZ0ljci1aeXc5TVBuZy1aaTRhbTN6Y0JJMm1SanFjMTJnQV9xbDZOWnhGWU9lbHN4ekNuRE1KT0MtQUZqR1h6TjktSnBZX2NhekJ6cjZ0em1IUDVD?oc=5", "source_name": "Stocks Down Under", "published_at": "2024-06-05T06:46:13+00:00", "published_display": "05 Jun 2024 06:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CHM Stock Price and Chart \u2014 ASX:CHM", "summary": "", "url": "https://news.google.com/rss/articles/CBMiV0FVX3lxTE9URlc5NWtvT2tCVndCZ3pYZW9tS0Z3VHU3NG1TeE5RRE9seFJfX0ctLU5TS3Y1QmxWMGFIUnVmLTFiLS1GSDFmR3IzTTRHeUlYdmhUOG84WQ?oc=5", "source_name": "TradingView", "published_at": "2021-01-18T12:01:57+00:00", "published_display": "18 Jan 2021 12:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 78, "total_relevant": 21, "sentiment_summary": {"positive": 1, "negative": 0, "neutral": 20, "score": 51, "total": 21, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 95, "events": [{"event": "general", "label": "Market update", "weight": 11.55, "count": 21}], "positive_events": 1, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 0.05, "latest_week": "2026-07-10", "one_week_move": -10.3, "four_week_move": -30.7, "twelve_week_move": -74.0, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.233027, "market_dynamics_buy_signal": false, "relative_strength": -77.526588, "fair_value_gap": -95.9, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 24.5734, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-10.3% over one week, -30.7% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 64, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Kalkine", "count": 11}, {"label": "Stocks Down Under", "count": 3}, {"label": "The Globe and Mail", "count": 2}, {"label": "Market source", "count": 1}, {"label": "Stockhead", "count": 1}, {"label": "Sharecafe", "count": 1}, {"label": "BiotechDispatch", "count": 1}, {"label": "TradingView", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 21}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 21}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "95/100 classification confidence."}, {"label": "Company focus", "value": "21", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-10.3% over one week, -30.7% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Chimeric Therapeutics Issues 325 Warrants as Part of Second Tranche Convertible Notes Placement"}], "updated_at": "2026-07-17T09:15:07.144488+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}